Aspirin and mortality from coronary bypass surgery

Area of Science:

• Cardiovascular Surgery
• Pharmacology
• Clinical Medicine

Background:

• Coronary bypass surgery lacks therapies to mitigate post-operative complications and mortality.
• Platelet activation is a key factor in atherosclerotic injury, suggesting a role for antiplatelet agents.

Purpose of the Study:

• To evaluate the efficacy of early aspirin administration in reducing mortality and ischemic complications following coronary bypass surgery.

Main Methods:

• A prospective study involving 5065 patients across 70 international centers, with 5022 surviving the initial 48 hours post-surgery.
• Data on 7500 variables per patient were collected, and outcomes were centrally adjudicated to determine the relationship between early aspirin use and patient outcomes.

Main Results:

• Aspirin use within 48 hours post-revascularization was associated with a significant reduction in mortality (1.3% vs. 4.0%, P<0.001).
• Aspirin therapy demonstrated substantial risk reductions for myocardial infarction (48%), stroke (50%), renal failure (74%), and bowel infarction (62%).
• Multivariate analysis confirmed aspirin's independent protective effect, with no increased risk of hemorrhage, gastritis, infection, or impaired wound healing.

Conclusions:

• Early aspirin administration following coronary bypass surgery is a safe and effective intervention.
• Aspirin use is linked to decreased mortality and a lower incidence of major ischemic complications affecting the heart, brain, kidneys, and gastrointestinal system.